Updates

EKF Diagnostics

March 2014

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

EKF has put out solid full year results with H2 showing a 13% increase in sales over H1. Overall, full year sales were Â£31.8m, up 22% whilst adjusted ebitda was up 51% to £4.8m. The main boost to the results came from an unexpected revival in sales of Biosen instruments (sales +75% to £6.5m). Demand had been expected to peter out but there has been a revival from diabetes clinics in Russia, Middle East and China. There was also higher than expected sales for the second year running of BHB, an enzymatic assay used on clinical chemistry analysers (+8% to Â£3.1m) where a competitor failed to regain its lost ground. Both are high margin areas but their revivals are somewhat unexpected. In terms of the new bits, QuoLab/ Quo ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Entertainment One - Trading ahead of forecasts

Parity

EKF Diagnostics (January 2015)

EKF Diagnostics (October 2014)

EKF Diagnostics (June 2014)

EKF Diagnostics - Three acquisitions in a month (April 2014)

EKF Diagnostics (October 2013)

EKF Diagnostics (April 2013)

EKF Diagnostics (October 2012)

EKF - Forecasts upgraded again (April 2012)

EKF DIagnostics (October 2011)

EKF - Second large diagnostic deal sends EKF full square into the US market (July 2011)

EKF Diagnostics (December 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X